2026 Drugs to Watch: Forecasting Pharmacy Impact with Artemetrx

The specialty drug pipeline is accelerating—and the financial implications for plans are significant. With new GLP-1 formulations, MASH therapies, and cell and gene therapy innovations on the horizon, early preparation is essential.

Join PSG experts for an exclusive webinar designed to help you discover which therapies will shape 2026, understand their potential financial impact on your plan, and learn proactive strategies to manage costs while maintaining quality care.

What You’ll Learn:

• Why Staying Ahead Matters – Leverage data to forecast which 2026 launches will affect your member population and budget most
• 2026 Drugs to Watch – Get expert analysis on high-impact therapies, including next-generation GLP-1s, emerging MASH treatments, and breakthrough cell and gene therapies
• Prepare with Confidence – Develop actionable strategies to position your plan for success before these therapies hit the market

Don’t wait until it’s too late. Equip your team with the insights needed to turn pipeline uncertainty into a strategic advantage.

Expert insight from our panelists:

Renee Rayburg, RPh

Vice President, Clinical Strategy

Travis Baughn, PharmD

VP, Business Development, Artemetrx

Steven Cramer

Director, Product Management